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Abstract
Epidemiological studies have demonstrated an increased leukemia incidence following ionizing radiation exposure, but to
date, the target cells and underlying mechanisms of radiation leukemogenesis remain largely unidentified. We engineered a
mouse model carrying a different fluorescent marker on each chromosome 2, located inside the minimum deleted region
occurring after radiation exposure and recognized as the first leukemogenic event. Using this tailored model, we report that
following radiation exposure, more than half of asymptomatic CBA Sfpi1GFP/mCh mice presented with expanding clones of
preleukemic hematopoietic cells harboring a hemizygous interstitial deletion of chromosome 2. Moreover, following
isolation of preleukemic hematopoietic stem and progenitor cells irradiated in their native microenvironment, we identified
the presence of Sfpi1 point mutations within a subpopulation of these preleukemic cells expanding rapidly (increasing from
6% to 55% in 21 days in peripheral blood in one case), hence identifying for the first time the presence of such cells within a
living animal. Importantly, we also report a previously undescribed gender difference in the phenotype of the preleukemic
cells and leukemia, suggesting a gender imbalance in the radiation-induced leukemic target cell. In conclusion, we provide
novel insights into the sequence of molecular events occurring during the (radiation-induced) leukemic clonal evolution.
Introduction
It is widely recognized that exposure to ionizing radiation
increases leukemia incidence [1–6]. Radiation leukemo-
genesis is a genetically complex, multistep process, and
the underlying mechanisms and target cells remain uni-
dentified [7]. The CBA inbred mouse strain is a model
of radiation-induced acute myeloid leukemia (rAML) [8, 9]
where hemizygous interstitial deletion of chromosome
2 (Del2) is a characteristic finding [10] with the minimal
deleted region (MDR) containing Sfpi1, encoding the
hematopoietic transcription factor PU.1 [11]. In ~85%
of the cases, the remaining Sfpi1 copy carries a point
mutation in a single CGC codon, within the DNA binding
domain in exon 5 [12]. These biallelic Sfpi1 aberrations
support a two-hit model in murine rAML [13]. Bone mar-
row (BM) cells carrying Del2 can be identified 24 h post-
irradiation, and it is assumed that Del2 HSPCs expand
clonally [14]. Ultimately, 15-20% of mice will present with
AML [15].
All data generated previously used fixed leukemic cells
to study Del2 and Sfpi1 mutations, thus limiting further
characterization of leukemogenesis. Here, we crossed
CBA Sfpi1GFP/GFP mice [16] with a newly generated CBA
Sfpi1mCh/mCh transgenic model to create an F1 CBA
Sfpi1mCh/GFP mouse expressing mCherry from a Rosa26
promotor construct located in the chromosome 2 MDR, and
GFP being expressed from the other allele under the Sfpi1
promoter. Monthly blood sampling post-irradiation was
used to monitor Del2, and preleukemic clonal expansion, by
flow cytometry.
We report that more than half of mice presented with
preleukemic cells harboring Del2. Moreover, we identified
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for the first time the presence of Sfpi1 point mutations
within subpopulations of these preleukemic cells, within
a living animal. We also provide evidence of a gender
difference in the (pre)leukemic phenotype, suggesting a
difference in the leukemic target cell between male and
female mice.
Methods
Mice, rAML induction, and tissue preparation
CBA Sfpi1mCh/mCh mice were generated as previously
described [17], and mated to CBA Sfpi1GFP/GFP mice [16] to
generate F1 CBA Sfpi1mCh/GFP mice. Mice were given sin-
gle 3Gy whole-body X-irradiation at 10-12 weeks of
age (70 males and 50 females). Sham-irradiation of age-
matched mice (n= 20; assigned at random) was performed
by placing the mice into the irradiator box for the appro-
priate time without X-rays being produced. rAMLs were
diagnosed as described previously [16], using the criteria of
the ‘Bethesda proposals for classification of nonlymphoid
neoplasms in mice’ [18]. Spleen tissue was stored at −70 °C
in RNAlater® (Ambion, Austin, US) for nucleic acid
extraction, in 4% formaldehyde for histopathological ana-
lysis, or disaggregated for FACS analysis, as described
previously [16]. All animal procedures conformed to the
UK Animals (Scientific Procedures) Act, 1986, Amendment
Regulations 2012, and animal experimental protocols were
reviewed and approved by the local Ethics Committee and
the Home Office.
Immunophenotyping of leukemic spleen cells
Spleen cells were incubated with phycoerythrin (PE)-con-
jugated antibodies: Sca1 (E13-161.7; BioLegend), cKit
(2B8; Abcam, Cambridge, UK), Flt3 (A2F10.1), Gr1 (1A8),
Ly6c (HK1.4; Abcam), Mac1 (M1/70), CD31 (MEC13.3),
CD3 (17A2), and B220 (RA3-6B2). All reagents were
purchased from BD Biosciences, unless otherwise stated.
Acquisition was performed using a Guava® easyCyte Single
Sample flow cytometer, and analyzed using InCyte™
software (Merck Millipore, Watford, UK).
DNA isolation from spleens and sequencing for
Sfpi1 exon 5 point mutation
DNA was extracted from spleen tissue using a DNeasy®
Blood & Tissue kit (Qiagen, Manchester, UK). Exon 5
mutations in Sfpi1 were determined by DNA sequencing as
described previously [19, 20], using primer sequences for-
ward 5′-CGACATGAAGGACAGCATCT-3′ and reverse 5′-
TTTCTTCACCTCGCCTGTCT-3′ (IDT, Leuven, Belgium).
PCR for mCherry and GFP construct detection
Detection of GFP construct was performed as previously
described [16]. For detection of the mCherry construct, primer
sequences were Cel1-F 5′-GTGACTCCCAACATCTGCCT-
3′, Cel1-R 5′-CTGCTTGCTTGCAGACTGAG-3′, Donor-
F3 5′-AAGGGCGAGGAGGATAACAT-3′ and Donor-R3
5′-CTTCAGCTTCAGCCTCTGCT-3′ (IDT).
Immunomagnetic cell separation and fluorescence-
activated cell sorting
Lin− cells were selected using EasySep™ Mouse Hema-
topoietic Progenitor Cell Enrichment Kit (Stem Cell
Technologies, Grenoble, France) and incubated with the
following antibodies conjugated with PE, PE-Cy5, PE-Cy7,
fluorescein isothiocyanate (FITC), allophycocyanin (APC)
or APCeFluor®780: Sca1 (D7), cKit (2B8), CD48 (HM48-
1), CD127 (A7R34), and CD150 (TC15-12F12.2; BioLe-
gend, San Diego, USA). All reagents were purchased from
Affymetrix (High Wycombe, UK), unless otherwise stated.
Flow cytometry acquisition and sorting was performed
using MoFlo XDP (Beckman Coulter, High Wycombe,
UK).
Pyrosequencing analysis
DNA was extracted from blood (10 µl) using DNeasy® kit
(Qiagen). Ten ng of DNA was used to amplify the target
sequence of Sfpi1 exon 5 by PCR with primer biotinylated
forward 5′-GCATCCAGAAGGGCAACC-3′ and reverse
5′-TCGCCTGTCTTGCCGTAGT-3′ primers generating a
79 bp PCR product. Primers, DNA and PyroMark PCR
master mix (Qiagen) were combined in a total volume of 25
µl, and amplified: 15 min at 95 °C, then 45 cycles of (30 s at
95 °C, 30 s at 60 °C and 30 s at 72 °C). Ten µl of the bio-
tinylated PCR product was used to detect mutations on the
first base of the 235th codon (CGC to TGC) with the fol-
lowing sequencing primer: 5′-CCTGTCTTGCCGTAGT-3′
using PyroMark48 (Qiagen).
Results
Clonal expansion of Del2 hematopoietic cells
following radiation exposure
Mice received 3 Gy whole-body X-irradiation and under-
went monthly tail vein bleeding for lifespan to identify
leukocytes carrying Del2, indicated by fluorescence
loss (Supplementary Figure S1A). In sham-irradiated
mice, all leukocytes expressed mCherry. GFP expression
is controlled by PU.1 promoter, hence lymphocytes did not
1436 T. Verbiest et al.
express GFP (i.e., mCherry+GFP−). Myeloid cells
(monocytes and granulocytes) require PU.1 for terminal
differentiation and maturation, and expressed GFP
throughout lifespan (i.e., mCherry+GFP+). Either PU.1
copy (mCherry or GFP) can be deleted during leukemic
transformation. However, mCherry loss was used as the
‘lead’ for detection of Del2, allowing GFP to be used as a
proxy for PU.1 expression from the remaining copy.
In irradiated animals, clonal expansion of mCherry
negative (mCherry−) leukocytes was detected as early as
3 months post-irradiation (Fig. 1a). At 9 months, the per-
centage of male mice with mCherry− leukocytes was
markedly higher compared with females (25% and 4%,
respectively), increasing to 70% for both at 18 months
(Fig. 1a). Interestingly, the percentage of female mice with
clonal expansion of only mCherry− lymphocytes was
markedly higher compared with males (54% and 39%,
respectively) at 18 months, and increased further by
21 months (Fig. 1a). At death, the percentage of male mice
with no mCherry− leukocytes (40% and 24%, respec-
tively), as well as mCherry− mixed myeloid–lymphoid
leukocytes was higher than in females (36% and 22%,
respectively; Fig. 1b). Importantly, almost twice as many-
females were diagnosed with leukemia compared with
males (16% and 9%, respectively; Fig. 1b). Irradiated
mice with Del2 clonal expansion and unirradiated mice
had similar WBC counts (6.8 ± 3.4 × 106/ml and 7.9 ±
2.6 × 106/ml, respectively). Only at the time of overt leu-
kemia presentation, WBC counts were increased (92.7 ±
121.8 × 106/ml).
Altered PU.1 expression in Del2 leukocytes and
hematopoietic progenitors
As most male mice presented with clonal expansion
in mCherry− myeloid–lymphoid leukocytes, we hypothe-
sized that Del2 occurred in a very primitive hematopoietic
cell type: hematopoietic stem cell (HSC) or multipotent
progenitor (MPP). To further characterize the cell of
origin, three irradiated male mice with mCherry−
myeloid–lymphoid leukocytes were killed. Flow cytometry
analysis showed that about 10% Lin− cells were
Fig. 1 Clonal expansion of mCherry− leukocytes in peripheral blood.
Blood of irradiated male and female CBA Sfpi1mCh/GFP mice (n= 70
and n= 50, respectively) was analyzed monthly for mCherry and GFP
expression. a Percentage of male (left panel) and female (right panel)
mice without mCherry loss (black), with both myeloid and lymphoid
mCherry loss (red), and with lymphoid mCherry loss (green), detected
in the blood, as a function of time following radiation exposure.
Number in the bar reflects the actual number of animals alive at the
time point. b Percentage of male (left panel) and female (right panel)
mice at time of death, diagnosed without mCherry loss (black), with
both myeloid and lymphoid mCherry loss (red), with lymphoid
mCherry loss (green) or with leukemia (white)
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mCherry−. Approximately 0.8% of mCherry−Lin− cells
were Sca1+cKit+, and half of the mCherry− LSK fraction
was CD48-CD150+ (i.e., LT-HSCs/MPP1), indicating that
these HSCs carried Del2 (Supplementary Figure S2A).
Similarly, mCherry− myeloid (i.e., mCherry−Lin−Sca1
−cKit+) and lymphoid progenitors (i.e., mCherry−Lin
−CD127+) were identified (Supplementary Figure S2B).
Interestingly, at 18 months, 54% of female mice had clonal
expansion of only mCherry− lymphocytes. Peripheral blood
analysis showed that ±50% of lymphocytes were mCherry−.
However, all monocytes and granulocytes were mCherry+
(Supplementary Figure S3B). BM analysis revealed that only
1.9% of Lin− cells were mCherry−, compared with 10% in
mice with clonal expansion in mCherry− myeloid–lymphoid
leukocytes. Almost all mCherry−Lin− cells were Sca1−cKit
− (96%). Although the cell number was low, in these sam-
ples no mCherry− HSCs or mCherry− myeloid progenitors
could be identified (Supplementary Figure S3A). However,
11% of mCherry−Lin− cells expressed CD127, indicating
that Del2 most likely occurred in an immature lymphoid cell
type (CLP; Supplementary Figure S3B).
To determine PU.1 expression changes on the remaining
chr2 after exposure, blood of male mice with clonal
expansion of mCherry− leukocytes was analyzed for
mCherry/GFP expression. When comparing GFP expres-
sion between mCherry− and mCherry+granulocytes,
mCherry− granulocytes had a markedly higher GFP
expression (Fig. 2a). Similarly, GFP expression was higher
in mCherry−Lin− than in mCherry+Lin− cells (Fig. 2b).
Exon 5 Sfpi1 point mutation is solely observed in
Del2 hematopoietic cells
There are data suggesting that the Sfpi1 point mutation most
probably leads to complete abolition of PU.1 activity [21,
22]. To identify and quantify the presence of the ‘second’
driving mutation, Lin− cells were sorted, based on their
mCherry expression, from irradiated male mice with
mCherry− blood leukocytes. mCherry allele loss occurred
specifically in the sorted mCherry− population (Fig. 3a).
Overall, 16% of mCherry−Lin− cells in mouse 2 had the
characteristic murine rAML C to T substitution, indicating
that these mutations are restricted to Del2 Lin− cells
(Fig. 3b). Point mutations were also analyzed in terminal
blood samples. Although not detectable in sham or irra-
diated CBA Sfpi1mCh/GFP mice with no mCherry− leuko-
cytes, 83% of irradiated mice harboring mCherry− clonal
expansion showed detectable levels of C to T substitution,
linking point mutation occurrence to a prior presence of
Del2 (data not shown). Previously, we reported that murine
CBA rAML cases without Sfpi1/PU.1 involvement are rare
(<10%; either as chromosome 2 deletion or as Sfpi1/PU.1
exon 5 mutation), and that within this subset of rAMLs,
~50% of cases has internal tandem duplications (ITDs)
within FMS-like tyrosine kinase 3 (Flt3) [23]. We have now
screened a panel of 134 murine rAML samples and found
Flt3-ITDs in 3% of the cases, none of them carrying dele-
tions or mutations of Sfpi1/PU.1. Interestingly, 2.2%
of cases carried a KRAS G12 mutation (manuscript in
preparation).
Simultaneous expansion of competing preleukemic
clones
At 15 months, one male mouse presented with an unusual
clonal expansion of both mCherry−/GFP+ and mCherry
+/GFP− leukocytes, with the point mutation detected in
blood leukocytes (6%; Fig. 4a). Three weeks later, the
point mutation had increased to 55% in blood (58% in
spleen; Fig. 4a) and mCherry−Lin−/mCherry+Lin− cells
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Fig. 2 GFP expression is upregulated in myeloid leukocytes following
Del2. a Blood of 8 male mice with clonal expansion in mCherry−
leukocytes was analyzed for mCherry and GFP expression. Mean GFP
fluorescence in mCherry+ and mCherry− granulocytes was compared
over time. Error bars indicate SEM. b Representative plots of GFP
expression in Lin− cells from a sham-irradiated male CBA Sfpi1wt/GFP
mouse, and an irradiated male CBA Sfpi1mCh/GFP mouse with clonal
expansion in mCherry− leukocytes (left and right panel, respectively).
GFP expression was higher in mCherry−Lin− cells, compared with
mCherry+Lin− cells
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were sorted. Despite being asymptomatic at sacrifice, this
mouse had leukemic pathological features, demonstrating
that appearance of the point mutation in Del2 blood cells
was indicative of a preleukemic mouse at least 1 month
prior to AML presentation. Hence, the point mutation
occurs late in the leukemogenic process, but presents a rapid
increase. Furthermore, both mCherry−/GFP+ and mCherry
+/GFP− leukocytes were detected. A schematic repre-
sentation of simultaneous expansion of two preleukemic
clones (one clone with GFP loss and one with mCherry
loss) is presented for this leukemic case (Fig. 4b). Sfpi1
mutation was analyzed in mCherry+Lin− and mCherry
−Lin− cells, and most mCherry− and mCherry+ cells
carried the mutation (63% and 71%, respectively); loss of
the GFP allele in mCherry+Lin− cells was also confirmed
(Fig. 4b).
Dysregulated PU.1 expression upon leukemic
progression
We demonstrated that following Del2, PU.1 expression on
the remaining homolog is upregulated, indicative of a
negative feedback mechanism; with upregulation of the
intact chr2 PU.1 promotor being a counter-balancing
mechanism. However, in several cases, this feedback
mechanism became dysregulated, possibly when the point
mutation occurs, resulting in leukemia development. At 6
months, GFP expression of mCherry− granulocytes slightly
decreased compared with mCherry+granulocytes (Fig. 5a).
By 9 months, GFP expression was no longer increased. One
month later, mCherry− leukocytes percentage had
increased further. Shortly thereafter, the mouse presented
with outward physical signs of rAML. Although still
expressing GFP, 93.5% of cells were mCherry−, indicating
Rosa26-mCherry chr2 homolog loss. Spleen cell immuno-
phenotyping showed that mCherry−GFP+ cells expressed
immaturity cell surface markers (Fig. 5b). Isolated DNA
from these cells revealed a TGC sequence. Blood smear
showed nucleated cells with blastic appearance while leu-
kemic spleen cells had lost Rosa26-mCherry construct
(Fig. 5c).
Notably, most female mice had clonal mCherry− lym-
phocytes expansion. Blood analysis of a female mouse
showed that myeloid leukocytes retained mCherry expres-
sion at 13 months but 1.9% of lymphocytes were mCherry
−, increasing further over time. At 17 months, the mouse
presented with AML. All mCherry− leukemic spleen cells
had lost mCherry and GFP expression, indicative of a
lymphoid origin. Immunophenotyping showed that cells
only expressed CD31 and B220 (Supplementary Figure
Fig. 3 Exon 5 Sfpi1 point mutation is solely observed in Del2 hema-
topoietic cells. a Lin− cells of male mice were sorted based on
mCherry expression. Absence of mCherry in mCherry−Lin− cells
was demonstrated [Rosa26-mCherry allele (510 bp); wild-type allele
(383 bp)]. b Schematic representation of sequence analyzed by pyr-
osequencing using sequencing primer complementary to biotinylated
forward strand. Pyrograms depict allele quantification for the first base
of the 235th codon of the Sfpi1 gene for mCherry+Lin− and mCherry
−Lin− cells. Pyrograms indicate the complementary sequence to the
forward strand, therefore the % of a indicates the lack or presence of
the mutation. Sanger sequencing profiles are presented as well for the
same mCherry+Lin− and mCherry−Lin− cells
Tracking preleukemic cells in vivo to reveal the sequence of molecular events in radiation leukemogenesis 1439
S4A), and no mutation was found on the remaining GFP
carrying chr2 homolog. On blood smear, most cells had
round nuclei and high nucleus to cytoplasm ratio (Supple-
mentary Figure S4B). Loss of Rosa26-mCherry construct
was confirmed. While leukemic cells did not express GFP
(i.e., PU.1 downregulation upon commitment towards the
lymphoid lineage), the GFP construct was still detectable by
PCR (Supplementary Figure S4C). Seven of the eight
female mice were diagnosed with lymphocytic leukemia,
while the remaining female was diagnosed with myeloid
leukemia, with a much shorter latency compared with male
AML cases (5 months and 11 months, respectively).
Fig. 4 Simultaneous expansion of competing preleukemic clones. a
Blood data of male mouse case 3 with mCherry− myeloid and lym-
phoid leukocytes. The mutation in the 235th codon of the Sfpi1 gene
(CGC to TGC) was analyzed at 15 months, and 21 days later at time of
sacrifice, by pyrosequencing of blood and spleen. b Schematic
representation of simultaneous clonal expansion of two preleukemic
clones with loss of Sfpi1 alleles (one with GFP and one with mCherry)
in this leukemia case. The mutation in the Sfpi1 gene was analyzed in
mCherry+Lin− and mCherry−Lin− cells. Pyrograms for allele
quantification for the first base of the 235th codon of the Sfpi1 gene are
presented for mCherry+Lin− and mCherry−Lin− cells. The presence
of GFP in mCherry+Lin− cells was analyzed by PCR. A blue star
depicts the presence of the mutation in the 235th codon of the Sfpi1
gene (CGC to TGC), red circle indicates mCherry and green circle
GFP
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Discussion
Using an engineered mouse model, we assessed Del2
occurrence after radiation exposure. A significant number of
studies into the cytogenetics of rAML in various inbred
mouse strains [24–26] revealed that structurally abnormal
chr2—usually consisting of large hemizygous interstitial
deletion (i.e., Del2)—occurs in ~90% of rAML cases, and
typically is detectable in 90–100% of the leukemic cells
within any sample [27]. It represents by far the most com-
mon and consistent chromosomal aberration seen in rAML
mouse models. Of the other cytogenetic abnormalities
identified in these studies, change in chromosome number is
the most frequent. In particular, loss or gain in Y chromo-
some. More recently, we performed array comparative
genomic hybridization (aCGH) at unprecedentedly high
Fig. 5 Leukemic progression following Sfpi1 dysregulation. a At 6
months, GFP expression in mCherry− granulocytes of a male mouse
had decreased slightly compared with mCherry− granulocytes at 4
months. GFP upregulation in mCherry− granulocytes decreased fur-
ther, and at 9 months, GFP expression was no longer different. b
mCherry−GFP+ spleen cells expressed immaturity cell surface mar-
kers. c Exon 5 Sfpi1 DNA sequence of the leukemic mouse zoomed in
on the CGC codon known to exhibit the point mutation (arrow indi-
cates the point mutation). Blood smear showed nucleated cells twofold
larger than RBCs with a blastic appearance. Confirmation of loss of
mCherry allele: control DNA was obtained from a wild-type mouse
and 2 sham-irradiated CBA Sfpi1mCh/GFP mice [Rosa26-mCherry allele
(510 bp) and wild-type allele (383 bp)]
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resolution on a unique panel of 79 CBA rAMLs [27].
Besides the characteristic Del2, small deletions were
observed on chrs 3, 4, 5, 6, 11, and 16 in individual cases,
but importantly no consistent event was identified.
At 9 months after radiation exposure, 25% of males
presented with mCherry− leukocytes, in line with pre-
viously reported percentages in irradiated mice with BM
Del2 clones, detected with cytogenetic methods [14]. All
these male mice had mCherry loss in both myeloid and
lymphoid lineages, indicative of a primitive hematopoietic
cell type (HSC or MPP1). Using SLAM markers, we
identified mCherry− HSCs (LSK CD48−CD150+) [28]
in mice with mixed lineage mCherry− clonal expansion in
blood. These mice had mCherry− myeloid and lymphoid
progenitors, based on differential CD127 expression in
these cells [29, 30], indicating that Del2 HSCs gave rise to
mCherry− daughter HSCs as well as mCherry− lineage-
committed progeny. At 15 months, 8 out of 18 males pre-
sented with lymphoid lineage-only mCherry− cells, indi-
cating that in these mice Del2 likely occurred in a
hematopoietic cell-like a CLP giving rise to lymphoid
progeny specifically.
We assessed PU.1 expression from the remaining chr2
homolog in mice with mCherry− leukocytes (GFP as
reporter for PU.1 transcription) [27, 31]. GFP expression in
mCherry− myelocytes was 1.4-fold higher compared with
mCherry+myelocytes. It can be directly attributed to an
increased PU.1 promoter activity through PU.1 auto-
regulation to compensate the loss of the second allele. It was
previously reported that both URE and Sfpi1 proximal
promoter have binding sites for PU.1 itself [32–34]. Here
we report that during leukemogenesis, autoregulation of
PU.1 was observed in mCherry− Lin− cells. This auto-
regulation becomes dysregulated, resulting in GFP expres-
sion decreasing to the level of mCherry+leukocytes. In
these cases, immunophenotyping showed immature phe-
notypes consistent with myeloid leukemia. We also con-
firmed that the remaining Sfpi1 copy carried a point
mutation replacing arginine 235 with cysteine (the most
common C to T substitution in murine rAMLs) [35] prob-
ably impairing transcriptional autoregulation. Our experi-
mental observations are consistent with a two-hit model of
murine radiation leukemogenesis in which the first irrever-
sible mutational hit (deletion of one Sfpi1 copy) results in
preleukemic cells with growth advantage. Subsequently,
they acquire a second mutational hit (point mutation in
the remaining Sfpi1), leading to full malignancy, clonal
expansion and leukemia [13].
It could be hypothesized that the point mutation occurs
when the GFP levels return to ‘normal’ levels (i.e., equal to
mCherry+ leukocytes), linking point mutation occurrence
with loss of PU.1 autoregulation. Data obtained from
terminal blood samples of irradiated mice revealed that 83%
of mice had mutated cells. In contrast, the point mutation
couldn’t be detected neither in sham-irradiated mice nor
irradiated mice without mCherry− leukocytes. In addition,
point mutations were exclusively detected in the BM
mCherry−Lin− cell fraction of mice with mCherry− leu-
kocytes. Most importantly, these observations link, for the
first time, the occurrence of the point mutation to a prior
presence of Del2. The leukemic case described with two
competing preleukemic clones provides evidence of how
rapid the leukemic progression occurs following acquisition
of the second hit (6% to 55% in merely three weeks). To the
best of our knowledge, only one study so far reported an
alternative mutation occurring in a mutually exclusive way
with Sfpi1/PU.1 [23]. RFLP and sequencing analysis
revealed in a subset of rAMLs the presence of Flt3-ITDs
(one of the most frequent mutations in human AMLs [36]).
These ITDs are similar to those seen in human AML cases
and the mutual exclusion with Sfpi1/PU.1 mutations sug-
gests that Flt3 mutations are driver mutations in these rare
rAML cases. We have now screened a panel of 134 CBA
rAML samples and found Flt3-ITDs in 3% of the cases
(unpublished data). Although this is clearly a minor path-
way, it represents the only significant alternative pathway to
rAML identified so far in this mouse model with a direct
link to human AML. In addition, we recently found a few
rAML with leukemic cells carrying a KRAS mutation con-
comitantly to Del2 and Sfpi1 mutations (data not shown),
none of them with additional Flt3-ITDs, suggesting differ-
ent leukemogenic pathways.
Overall male rAML incidence was 9% with an average
latency of 11 months, consistent with previous work in male
CBA mice [8, 16, 37]. One in three females had mCherry−
lymphoid but not myeloid leukocytes at 12 months. The
mean leukemic latency was similar to males (i.e., 13 and
11 months, respectively; P= 0.49). All but one male leu-
kemia cases were categorized as myeloid leukemia. In
contrast, 7 out of 8 female leukemia cases were categorized
as lymphoid leukemia. Previous work reported AML inci-
dences higher among irradiated males than females. [16,
38–40] Our data suggest that a gender-specific hemato-
poietic cell subpopulation leads to clonal expansion (HSC/
MPP1 vs CLP). Interestingly, PU.1-knockout in lymphoid
progenitors does not alter B-cell-maturation or proliferation
[41], possibly explaining the mature B-cell phenotype in our
female AMLs (i.e., B220 expression). On the other hand,
PU.1-knockout in myeloid progenitors inhibits their
maturation but not their proliferation [41], consistent with
the immature myeloid phenotype observed in our male
AMLs. However, we assume that all lineages are prone to
Del2 to the same extent, but that cell intrinsic or external
factors promoting their expansion, may be gender-specific.
An intrinsic gender-specific radiosensitivity is highly
unlikely, and albeit not yet well understood, sex hormones
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might have a pivotal role. For example, castration does not
affect rAML incidence, whereas ovariectomy results in a
twofold increase [42]. Interestingly, gonadectomy does not
alter leukemia incidence in unexposed mice [42]. It was also
shown that estrogen binding to its receptor enhanced HSC
self-renewal by upregulation of cell-cycle genes [43].
Follow-up of atomic bomb survivors reported that female
AML baseline rate is ~40% of that for men who displayed a
more rapid increased AML incidence rate with attained age
[1]. In conclusion, we propose, based on our experimental
data, a model with gender dependent leukemic pathways
(Supplementary Figure S5). Our study provides novel
insights into (radiation) leukemogenesis, and the model
should enable further deciphering of this complex multistep
process.
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